PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

PolyPid Ltd.

We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes.
Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications.
Our product candidates are designed to deliver medications in the body over days to several months in a controlled manner.  This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation and cancer.
Our initial infection treatment targets are Surgical Site Infections (SSIs), the second most prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative impact on patients’ clinical outcomes and also pose a significant healthcare system burden.
We strive to reduce overall surgical infection rates, including infections due to antibiotic-resistant bacteria which the FDA defined as being one of the world’s most pressing public health problems.

NASDAQ: PYPD

Kreos Capital

GUIBOR

Financiere Saint James

Shavit Capital

Aurum Ventures

Chaim Hurvitz

Apple Core Holdings

PolyPid Ltd. 

We are PolyPid! A global late-stage biopharmaceutical company focused on developing, manufacturing, and commercializing novel, locally administered extended-release therapeutics. Watch the process: https://lnkd.in/dBRm8Dn 
#LayerByLayer

We will be in sunny Miami for the 26th Barclays Investment Bank #Healthcare Conference. Please reach out to your Barclays representative or to Ori Warshavsky to schedule a meeting.
See full announcement here: https://bit.ly/3OZjSTp


Our #SHIELD II #phase3  trial is progressing as planned. #Topline results expected in second half of 2024. See announcement here: https://bit.ly/498jWIz

#ssi #clinicaltrials #LayerByLayer

NASDAQ:PYPD

PolyPid

Last Close

3.44

08/11 21:00

Market Cap

6.65M

Beta: 1.25

Volume Today

3.35K

Avg: 95.94K

PE Ratio

−0.46

PFCF: −0.35

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics